Tuesday, January 22, 2013

Denmark strives to create a simple clinical trials process

Creating clinical trials in an environment where there isn't much red tape and process delay is very difficult.  But one country is trying to change this.  Denmark wants to streamline clinical trials in their country to attract more Pharma companies to their country.  They are striving to create a system where it's easy to begin trials with human subjects.  They've also created an application process where companies submit one form to the health agency and the health research ethics board.  They're even begun discussions of creating a pairing service to digitally match participants to clinical trials they'd fit with.

According to The Copenhagen Post:
“Large pharmaceutical companies avoid Denmark because they think it is too expensive to recruit researchers and administrative staff for trials,” Gluud said. “The new initiatives will at least make the administrative side easier. It might also create more awareness about the Danish health and research sector, which are both of a high quality, and in doing so attract more foreign investment generally.”

It's clear that Denmark is showing initiative to streamline their clinical trial process to attract more Pharma companies to conduct trials in their region.  This April at Partnerships in Clinical Trials, during the presentation Dissecting Virtual Pharma Model: Benefit from Best Practices, representatives from Arno Therapeutics and Dragon Bio-Consultants will be on hand to discuss life cycle decisions through the product development process to lower the cost and quickly move drugs through the clinical trial process. If you'd like more information on this session and the rest on the program, download the agenda. If you'd like to join us, as a reader of this blog when you register to join us and mention code XP1800BLOG, you'll save 15% off the standard rate.

Do initiatives like this encourage companies to expand in new regions? How can companies eliminating strenuous standards increase their ability to handle clinical trials?

No comments: